BR0214564A - Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos - Google Patents

Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos

Info

Publication number
BR0214564A
BR0214564A BR0214564-2A BR0214564A BR0214564A BR 0214564 A BR0214564 A BR 0214564A BR 0214564 A BR0214564 A BR 0214564A BR 0214564 A BR0214564 A BR 0214564A
Authority
BR
Brazil
Prior art keywords
antineoplastic agents
fpt inhibitor
treatment processes
cancer treatment
medicament
Prior art date
Application number
BR0214564-2A
Other languages
English (en)
Portuguese (pt)
Inventor
David L Cutler
Michael L Meyers
Charles Baum
Sara L Zaknoen
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR0214564A publication Critical patent/BR0214564A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0214564-2A 2001-11-30 2002-11-25 Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos BR0214564A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33441101P 2001-11-30 2001-11-30
PCT/US2002/037954 WO2003047697A2 (en) 2001-11-30 2002-11-25 Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer

Publications (1)

Publication Number Publication Date
BR0214564A true BR0214564A (pt) 2004-11-09

Family

ID=23307076

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214564-2A BR0214564A (pt) 2001-11-30 2002-11-25 Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos

Country Status (13)

Country Link
US (2) US20030185831A1 (https=)
EP (1) EP1448268A2 (https=)
JP (1) JP2005511663A (https=)
CN (2) CN1617755A (https=)
AU (1) AU2002352941A1 (https=)
BR (1) BR0214564A (https=)
CA (1) CA2468839A1 (https=)
HU (1) HUP0402401A2 (https=)
MX (1) MXPA04005207A (https=)
NO (1) NO20042730L (https=)
NZ (1) NZ532562A (https=)
WO (1) WO2003047697A2 (https=)
ZA (1) ZA200403737B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533838A (ja) * 2002-07-24 2005-11-10 ノバルティス アクチエンゲゼルシャフト 未分化甲状腺癌を処置するための4−(4−メチルピペラジン−1−イルメチル)−n−[4−メチル−3−(4−ピリジン−3−イル)ピリミジン−2−イルアミノ]フェニル]−ベンズアミド
CA2439440A1 (en) * 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
CA2544421A1 (en) * 2003-11-06 2005-05-26 Schering Corporation Combination of a farnesyl transferase inhibitor with an antihormonal agent for the treatment of breast cancer
JP2007525507A (ja) * 2004-02-26 2007-09-06 ザ ペン ステイト リサーチ ファンデーション オピオイド増殖因子レセプターを用いる、新生物の処置のための組み合わせ療法
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20080255171A1 (en) * 2005-10-07 2008-10-16 Manley Paul W Combination of Nilotinib with Farnesyl Transferase Inhibitors
WO2008051531A2 (en) * 2006-10-25 2008-05-02 Schering Corporation Discontinuous methods of treating cancer
WO2008067144A2 (en) * 2006-11-28 2008-06-05 Smithkline Beecham (Cork) Limited Cancer treatment method
US20230390197A1 (en) * 2020-10-27 2023-12-07 Wisconsin Alumni Research Foundation Modular dendron micelles for combination immunotherapy
AU2023376684A1 (en) 2022-11-09 2025-06-19 Merck Patent Gmbh Toll-like receptor 7 agonists as immune-stimulators to elicit the innate antitumor immunity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
DK1041985T3 (da) * 1997-12-22 2006-06-19 Schering Corp Kombination af benzocycloheptapyridinforbindelser og antineoplastiske lægemidler til behandling af profilerative sygdomme
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
JP5491681B2 (ja) * 2000-02-04 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
US6838467B2 (en) * 2000-02-24 2005-01-04 Janssen Pharmaceutica N. V. Dosing regimen
CA2397448A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
JP2003525239A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
EP1322334A2 (en) * 2000-10-05 2003-07-02 George Q. Daley Methods of inducing cancer cell death and tumor regression

Also Published As

Publication number Publication date
NO20042730L (no) 2004-06-29
WO2003047697A2 (en) 2003-06-12
AU2002352941A1 (en) 2003-06-17
ZA200403737B (en) 2005-05-23
WO2003047697A3 (en) 2003-10-30
MXPA04005207A (es) 2004-08-19
US20060183765A1 (en) 2006-08-17
CA2468839A1 (en) 2003-06-12
JP2005511663A (ja) 2005-04-28
HUP0402401A2 (hu) 2005-03-29
EP1448268A2 (en) 2004-08-25
CN101181269A (zh) 2008-05-21
NZ532562A (en) 2007-02-23
US20030185831A1 (en) 2003-10-02
CN1617755A (zh) 2005-05-18

Similar Documents

Publication Publication Date Title
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
BR9906581A (pt) Processo para administração de taxano encapsulado em lipossomos
BR0208373A (pt) Inibidores da tirosina cinase
BR0312464A (pt) Inibidores de tirosina quinases
TR200002243T2 (tr) Arsenik trioksitin hazırlanması için işlem ve bunların kanser tedavisi için kullanımı.
PA8479201A1 (es) Derivados del acido hidroxi-pipecolato hidroxamico
MXPA04005425A (es) Uso de inhibidores de farnesil proteina transferasa y por lo menos dos agentes antineoplasicos en el tratamiento de cancer.
MXPA04001876A (es) Uso de fucanos en el tratamiento de adhesiones, artritis y psoriasis.
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
WO2002102306A8 (en) Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
BR0213424A (pt) Uso aperfeiçoado de composto antitumoral na terapia contra câncer
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
BRPI0510657A (pt) tratamento com cisplatina e com um inibidor de egfr
BR0214564A (pt) Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos
BR0315942A (pt) Tratamento de doenças e condições mediadas pelo aumento de fosforilação
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
PT1085884E (pt) Combinacao de compostos seleniferos com gemcitabina ou mitomicina c
WO2004012746A3 (en) New uses for inhibitors of inosine monophosphate dehydrogenase
BRPI0413410A (pt) co-administração de um polissacarìdeo com um agente quimioterapêutico para o tratamento de cáncer
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 DA RPI 2108 DE 31/05/2011.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/4545 (2006.01), A61P 35/00 (2006.01)